Insider Trading Alert - REGN, SZYM And SPW Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, March 21, 2014, 95 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $237.64 to $58,561,295.00.

Highlighted Stocks Traded by Insiders:

Regeneron Pharmaceuticals (REGN) - FREE Research Report

Sanofi who is 10% Owner at Regeneron Pharmaceuticals bought 67,703 shares at $328.33 on March 21, 2014. Following this transaction, the 10% Owner owned 18.2 million shares meaning that the stake was reduced by 0.37% with the 67,703-share transaction.

The shares most recently traded at $310.79, down $17.54, or 5.64% since the insider transaction. Historical insider transactions for Regeneron Pharmaceuticals go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 17,000

The average volume for Regeneron Pharmaceuticals has been 1.0 million shares per day over the past 30 days. Regeneron Pharmaceuticals has a market cap of $32.2 billion and is part of the health care sector and drugs industry. Shares are up 19.65% year-to-date as of the close of trading on Thursday.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. The company has a P/E ratio of 87.4. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on REGN - FREE

TheStreet Quant Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Solazyme (SZYM) - FREE Research Report

Wolfson Jonathan S who is Chief Executive Officer at Solazyme sold 35,000 shares at $13.64 on March 21, 2014. Following this transaction, the Chief Executive Officer owned 2.6 million shares meaning that the stake was reduced by 1.32% with the 35,000-share transaction.

The shares most recently traded at $13.36, down $0.28, or 2.09% since the insider transaction. Historical insider transactions for Solazyme go as follows:

  • 4-Week # shares sold: 53,114
  • 12-Week # shares sold: 70,614
  • 24-Week # shares sold: 103,114

The average volume for Solazyme has been 1.0 million shares per day over the past 30 days. Solazyme has a market cap of $995.0 million and is part of the basic materials sector and energy industry. Shares are up 32.05% year-to-date as of the close of trading on Thursday.

Solazyme, Inc. manufactures and sells renewable oils and other bioproducts. Its proprietary technology transforms a range of plant-based sugars into triglyceride oils and other bioproducts. Currently there are 7 analysts that rate Solazyme a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SZYM - FREE

TheStreet Quant Ratings rates Solazyme as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Solazyme Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

SPX Corporation (SPW) - FREE Research Report

Relational Investors Llc who is 10% Owner at SPX Corporation sold 214,763 shares at $101.62 on March 21, 2014. Following this transaction, the 10% Owner owned 6.4 million shares meaning that the stake was reduced by 3.22% with the 214,763-share transaction.

The shares most recently traded at $99.84, down $1.78, or 1.78% since the insider transaction. Historical insider transactions for SPX Corporation go as follows:

  • 4-Week # shares sold: 19,686
  • 12-Week # shares sold: 34,686
  • 24-Week # shares sold: 37,686

The average volume for SPX Corporation has been 311,600 shares per day over the past 30 days. SPX Corporation has a market cap of $4.6 billion and is part of the industrial goods sector and industrial industry. Shares are up 1.28% year-to-date as of the close of trading on Thursday.

SPX Corporation provides specialized engineered solutions worldwide. It primarily operates in two segments, Flow Technology, and Thermal Equipment and Services. The stock currently has a dividend yield of 1.46%. The company has a P/E ratio of 23.8. Currently there are 8 analysts that rate SPX Corporation a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPW - FREE

TheStreet Quant Ratings rates SPX Corporation as a buy. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and good cash flow from operations. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full SPX Corporation Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Asia Markets Fall on Latest Tariff Threats From Trump

Asia Markets Fall on Latest Tariff Threats From Trump

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

Google Invests in JD.com; Comcast-Disney Battle Nears Head -- ICYMI

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

REPLAY: Jim Cramer on Tariff Worries, Oil, Alphabet and Centene

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Video: Athens Stock Exchange CEO on What's Next for Greece's Debt Woes

Dow Drops Over 100 Points on Trade War Worries

Dow Drops Over 100 Points on Trade War Worries